Parkinsonism in patients with a history of amphetamine exposure
Identifieur interne : 001F49 ( Main/Merge ); précédent : 001F48; suivant : 001F50Parkinsonism in patients with a history of amphetamine exposure
Auteurs : Chadwick W. Christine [États-Unis] ; Elisabeth R. Garwood [États-Unis] ; Lauren E. Schrock [États-Unis] ; Daniel E. Austin [États-Unis] ; Charles E. Mcculloch [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-01-30.
English descriptors
- KwdEn :
- Adult, Amphetamine (poisoning), Amphetamine-Related Disorders (epidemiology), Amphetamine-Related Disorders (etiology), Case-Control Studies, Dopamine Agents (poisoning), Environmental Exposure, Female, Follow-Up Studies, Humans, Male, Medical Records, Middle Aged, Parkinsonian Disorders (chemically induced), Parkinsonian Disorders (epidemiology), Parkinsonian Disorders (physiopathology), Questionnaires, Retrospective Studies, Risk Factors, Time Factors, neurotoxicant, neurotoxin, selective vulnerability.
- MESH :
- chemical , poisoning : Amphetamine, Dopamine Agents.
- chemically induced : Parkinsonian Disorders.
- epidemiology : Amphetamine-Related Disorders, Parkinsonian Disorders.
- etiology : Amphetamine-Related Disorders.
- physiopathology : Parkinsonian Disorders.
- Adult, Case-Control Studies, Environmental Exposure, Female, Follow-Up Studies, Humans, Male, Medical Records, Middle Aged, Questionnaires, Retrospective Studies, Risk Factors, Time Factors.
Abstract
We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of patients with PD with prolonged amphetamine exposure with unexposed patients with PD. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine‐exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use. © 2009 Movement Disorder Society
Url:
- https://api.istex.fr/document/13231344BAE719D1985262921EA0739AE1D6AF96/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831101
DOI: 10.1002/mds.22915
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000346
- to stream Istex, to step Curation: 000346
- to stream Istex, to step Checkpoint: 000792
- to stream Pmc, to step Corpus: 000076
- to stream Pmc, to step Curation: 000076
- to stream Pmc, to step Checkpoint: 000319
- to stream PubMed, to step Corpus: 001A33
- to stream PubMed, to step Curation: 001A33
- to stream PubMed, to step Checkpoint: 001710
- to stream Ncbi, to step Merge: 002969
- to stream Ncbi, to step Curation: 002969
- to stream Ncbi, to step Checkpoint: 002969
Links to Exploration step
ISTEX:13231344BAE719D1985262921EA0739AE1D6AF96Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:13231344BAE719D1985262921EA0739AE1D6AF96</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.22915</idno>
<idno type="url">https://api.istex.fr/document/13231344BAE719D1985262921EA0739AE1D6AF96/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000346</idno>
<idno type="wicri:Area/Istex/Curation">000346</idno>
<idno type="wicri:Area/Istex/Checkpoint">000792</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Christine C:parkinsonism:in:patients</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831101</idno>
<idno type="RBID">PMC:2831101</idno>
<idno type="wicri:Area/Pmc/Corpus">000076</idno>
<idno type="wicri:Area/Pmc/Curation">000076</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000319</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001A33</idno>
<idno type="wicri:Area/PubMed/Curation">001A33</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001710</idno>
<idno type="wicri:Area/Ncbi/Merge">002969</idno>
<idno type="wicri:Area/Ncbi/Curation">002969</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002969</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Christine C:parkinsonism:in:patients</idno>
<idno type="wicri:Area/Main/Merge">001F49</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
<affiliation wicri:level="2"><country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Neurology, University of California, San Francisco</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Pennsylvania State University College of Medicine, Hershey</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Utah</region>
</placeName>
<wicri:cityArea>Department of Neurology, University of Utah, Salt Lake City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maine (État)</region>
</placeName>
<wicri:cityArea>Colby College, Waterville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
<affiliation wicri:level="2"><country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Epidemiology and Biostatistics, University of California, San Francisco</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-01-30">2010-01-30</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="228">228</biblScope>
<biblScope unit="page" to="231">231</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">13231344BAE719D1985262921EA0739AE1D6AF96</idno>
<idno type="DOI">10.1002/mds.22915</idno>
<idno type="ArticleID">MDS22915</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Amphetamine (poisoning)</term>
<term>Amphetamine-Related Disorders (epidemiology)</term>
<term>Amphetamine-Related Disorders (etiology)</term>
<term>Case-Control Studies</term>
<term>Dopamine Agents (poisoning)</term>
<term>Environmental Exposure</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Medical Records</term>
<term>Middle Aged</term>
<term>Parkinsonian Disorders (chemically induced)</term>
<term>Parkinsonian Disorders (epidemiology)</term>
<term>Parkinsonian Disorders (physiopathology)</term>
<term>Questionnaires</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
<term>neurotoxicant</term>
<term>neurotoxin</term>
<term>selective vulnerability</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="poisoning" xml:lang="en"><term>Amphetamine</term>
<term>Dopamine Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Amphetamine-Related Disorders</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Amphetamine-Related Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Case-Control Studies</term>
<term>Environmental Exposure</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Medical Records</term>
<term>Middle Aged</term>
<term>Questionnaires</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of patients with PD with prolonged amphetamine exposure with unexposed patients with PD. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine‐exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use. © 2009 Movement Disorder Society</div>
</front>
</TEI>
<double doi="10.1002/mds.22915"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:13231344BAE719D1985262921EA0739AE1D6AF96</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.22915</idno>
<idno type="url">https://api.istex.fr/document/13231344BAE719D1985262921EA0739AE1D6AF96/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000346</idno>
<idno type="wicri:Area/Istex/Curation">000346</idno>
<idno type="wicri:Area/Istex/Checkpoint">000792</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Christine C:parkinsonism:in:patients</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
<affiliation wicri:level="2"><country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Neurology, University of California, San Francisco</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Pennsylvania State University College of Medicine, Hershey</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Utah</region>
</placeName>
<wicri:cityArea>Department of Neurology, University of Utah, Salt Lake City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maine (État)</region>
</placeName>
<wicri:cityArea>Colby College, Waterville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
<affiliation wicri:level="2"><country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Epidemiology and Biostatistics, University of California, San Francisco</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-01-30">2010-01-30</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="228">228</biblScope>
<biblScope unit="page" to="231">231</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">13231344BAE719D1985262921EA0739AE1D6AF96</idno>
<idno type="DOI">10.1002/mds.22915</idno>
<idno type="ArticleID">MDS22915</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>neurotoxicant</term>
<term>neurotoxin</term>
<term>selective vulnerability</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of patients with PD with prolonged amphetamine exposure with unexposed patients with PD. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine‐exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use. © 2009 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
<PMC><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
<affiliation wicri:level="3"><nlm:aff id="A1">Department of Neurology, University of California, San Francisco</nlm:aff>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
<wicri:orgArea>Department of Neurology, University of California</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
<affiliation><nlm:aff id="A2">Pennsylvania State University College of Medicine</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
<affiliation><nlm:aff id="A3">Department of Neurology, University of Utah</nlm:aff>
<wicri:noCountry code="subfield">University of Utah</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
<affiliation><nlm:aff id="A4">Colby College</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
<affiliation wicri:level="3"><nlm:aff id="A5">Department of Epidemiology and Biostatistics University of California, San Francisco</nlm:aff>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
<wicri:orgArea>Department of Epidemiology and Biostatistics University of California</wicri:orgArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">20063432</idno>
<idno type="pmc">2831101</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831101</idno>
<idno type="RBID">PMC:2831101</idno>
<idno type="doi">10.1002/mds.22915</idno>
<date when="2010">2010</date>
<idno type="wicri:Area/Pmc/Corpus">000076</idno>
<idno type="wicri:Area/Pmc/Curation">000076</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000319</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001A33</idno>
<idno type="wicri:Area/PubMed/Curation">001A33</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001710</idno>
<idno type="wicri:Area/Ncbi/Merge">002969</idno>
<idno type="wicri:Area/Ncbi/Curation">002969</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002969</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Christine C:parkinsonism:in:patients</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Parkinsonism in patients with a history of amphetamine exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
<affiliation wicri:level="3"><nlm:aff id="A1">Department of Neurology, University of California, San Francisco</nlm:aff>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
<wicri:orgArea>Department of Neurology, University of California</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
<affiliation><nlm:aff id="A2">Pennsylvania State University College of Medicine</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
<affiliation><nlm:aff id="A3">Department of Neurology, University of Utah</nlm:aff>
<wicri:noCountry code="subfield">University of Utah</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
<affiliation><nlm:aff id="A4">Colby College</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
<affiliation wicri:level="3"><nlm:aff id="A5">Department of Epidemiology and Biostatistics University of California, San Francisco</nlm:aff>
<country>États-Unis</country>
<placeName><settlement type="city">San Francisco</settlement>
<region type="state">Californie</region>
</placeName>
<wicri:orgArea>Department of Epidemiology and Biostatistics University of California</wicri:orgArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Amphetamine (poisoning)</term>
<term>Amphetamine-Related Disorders (epidemiology)</term>
<term>Amphetamine-Related Disorders (etiology)</term>
<term>Case-Control Studies</term>
<term>Dopamine Agents (poisoning)</term>
<term>Environmental Exposure</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Medical Records</term>
<term>Middle Aged</term>
<term>Parkinsonian Disorders (chemically induced)</term>
<term>Parkinsonian Disorders (epidemiology)</term>
<term>Parkinsonian Disorders (physiopathology)</term>
<term>Questionnaires</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="poisoning" xml:lang="en"><term>Amphetamine</term>
<term>Dopamine Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Amphetamine-Related Disorders</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Amphetamine-Related Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Case-Control Studies</term>
<term>Environmental Exposure</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Medical Records</term>
<term>Middle Aged</term>
<term>Questionnaires</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P6">We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g. manganese), we sought to compare the clinical features of PD patients with <italic>prolonged</italic>
amphetamine exposure with unexposed PD patients. <underline>Prolonged exposure</underline>
was defined as a minimum of twice a week for ≥ 3 months, or weekly use ≥ 1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine-exposed group (49.8 ± 8.2 years vs. 53.1 ±7.4 years; p < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use.</p>
</div>
</front>
</TEI>
</PMC>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F49 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 001F49 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:13231344BAE719D1985262921EA0739AE1D6AF96 |texte= Parkinsonism in patients with a history of amphetamine exposure }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |